{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:07:33Z","timestamp":1791058053779,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K13536"],"award-info":[{"award-number":["24K13536"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01572-0","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:28:15Z","timestamp":1783582095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-258X","authenticated-orcid":false,"given":"Yuki","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyasu","family":"Kouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nakatoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"1","key":"1572_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","volume":"21","author":"D Wu","year":"2023","unstructured":"Wu D, Li L, Wen Z, Wang G (2023) Romosozumab in osteoporosis: yesterday, today and tomorrow. J Transl Med 21(1):668. https:\/\/doi.org\/10.1186\/s12967-023-04563-z","journal-title":"J Transl Med"},{"issue":"8","key":"1572_CR2","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1111\/bcp.14749","volume":"87","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K, Kawarasaki S, Hata T, Yoshizaki A, Nakamura M, Ikuma M (2021) Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. Br J Clin Pharmacol 87(8):3279\u20133291. https:\/\/doi.org\/10.1111\/bcp.14749","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"16","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"1","key":"1572_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14(1):59. https:\/\/doi.org\/10.1007\/s11657-019-0608-z","journal-title":"Arch Osteoporos"},{"issue":"9","key":"1572_CR6","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jdsr.2021.11.003","volume":"58","author":"M Tsuneishi","year":"2022","unstructured":"Tsuneishi M, Yamamoto T, Yamaguchi T, Kodama T, Sato T (2022) Use of the dental formula from the national database of health insurance claims and specific health checkups of Japan. Jpn Dent Sci Rev 58:52\u201358. https:\/\/doi.org\/10.1016\/j.jdsr.2021.11.003","journal-title":"Jpn Dent Sci Rev"},{"issue":"1","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/87551225221144960","volume":"39","author":"K Kotake","year":"2023","unstructured":"Kotake K, Mitsuboshi S, Omori Y, Kawakami Y, Kawakami Y (2023) Evaluation of risk of cardiac or cerebrovascular events in romosozumab users focusing on comorbidities: analysis of the Japanese adverse drug event report database. J Pharm Technol: jPT: Off Publ Assoc of Pharm Tech 39(1):23\u201328. https:\/\/doi.org\/10.1177\/87551225221144960","journal-title":"J Pharm Technol: jPT: Off Publ Assoc of Pharm Tech"},{"issue":"3","key":"1572_CR9","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","volume":"110","author":"J Stokar","year":"2025","unstructured":"Stokar J, Szalat A (2025) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab 110(3):e861\u2013e867. https:\/\/doi.org\/10.1210\/clinem\/dgae173","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1572_CR10","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00198-024-07255-6","volume":"35","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35(12):2165\u20132174. https:\/\/doi.org\/10.1007\/s00198-024-07255-6","journal-title":"Osteoporos Int"},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.37737\/ace.2.1_13","volume":"2","author":"N Hirose","year":"2020","unstructured":"Hirose N, Ishimaru M, Morita K, Yasunaga H (2020) A review of studies using the Japanese national database of health insurance claims and specific health checkups. Ann Clin Epidemiol 2:13\u201326. https:\/\/doi.org\/10.37737\/ace.2.1_13","journal-title":"Ann Clin Epidemiol"},{"issue":"3\u20134","key":"1572_CR12","first-page":"55","volume":"6","author":"S Matsuda","year":"2012","unstructured":"Matsuda S, Fujimori K (2012) The claim database in Japan. Asian Pacific J Dis Manag 6(3\u20134):55\u201359","journal-title":"Asian Pacific J Dis Manag"},{"key":"1572_CR13","unstructured":"Japanese Ministry of Health Labour, and Welfare (2016) Proportion of electronic claims in the Japanese health insurance system. Japanese Ministry of Health, Labour, and Welfare. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000099002.pdf. Accessed 18 June 2026"},{"key":"1572_CR14","unstructured":"Japanese Ministry of Health Labour, and Welfare (2017) NDB open data. Japanese Ministry of Health, Labour, and Welfare. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000193322.pdf. Accessed 18 June 2026"},{"issue":"5","key":"1572_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"11","key":"1572_CR16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130\u20131139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"issue":"1","key":"1572_CR17","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1038\/s41467-022-31997-8","volume":"13","author":"Y Yu","year":"2022","unstructured":"Yu Y, Wang L, Ni S, Li D, Liu J, Chu HY, Zhang N, Sun M, Li N, Ren Q, Zhuo Z, Zhong C, Xie D, Li Y, Zhang ZK, Zhang H, Li M, Zhang Z, Chen L, Pan X, Xia W, Zhang S, Lu A, Zhang BT, Zhang G (2022) Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat Commun 13(1):4241. https:\/\/doi.org\/10.1038\/s41467-022-31997-8","journal-title":"Nat Commun"},{"issue":"4","key":"1572_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.4503","volume":"37","author":"A De Mar\u00e9","year":"2022","unstructured":"De Mar\u00e9 A, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687\u2013699. https:\/\/doi.org\/10.1002\/jbmr.4503","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1572_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5543\/tkda.2023.61595","volume":"51","author":"Y Y\u00fcksel","year":"2023","unstructured":"Y\u00fcksel Y, Y\u0131ld\u0131z C, Rak\u0131c\u0131 IT (2023) Relationship between sclerostin levels and coronary artery calcification and plaque composition. Turk Kardiyol Dern Ars 51(4):266\u2013273. https:\/\/doi.org\/10.5543\/tkda.2023.61595","journal-title":"Turk Kardiyol Dern Ars"},{"key":"1572_CR20","unstructured":"Pharmaceuticals and Medical Devices Agency (2019) Revision of precautions: romosozumab (genetically engineered). https:\/\/www.pmda.go.jp\/files\/000231400.pdf. Accessed 18 June 2026"},{"key":"1572_CR21","unstructured":"U. S. Food and Drug Administration (2019) Evenity: drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761062s000lbl.pdf. Accessed 18 June 2026"},{"key":"1572_CR22","unstructured":"European Medicines Agency (2019) Approval of the marketing authorisation for evenity (romosozumab) https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-and-answers-approval-marketing-authorisation-evenity-romosozumab_en.pdf. Accessed 18 June 2026 2026"},{"issue":"21","key":"1572_CR23","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","volume":"56","author":"S Elmariah","year":"2010","unstructured":"Elmariah S, Delaney JA, O\u2019Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, Halperin JL (2010) Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis). J Am Coll Cardiol 56(21):1752\u20131759. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.050","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1572_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"CW Sing","year":"2018","unstructured":"Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33(8):1422\u20131434. https:\/\/doi.org\/10.1002\/jbmr.3448","journal-title":"J Bone Miner Res"},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 252:106\u2013115. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.06.039","journal-title":"Atherosclerosis"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01572-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01572-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01572-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:28:17Z","timestamp":1783582097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01572-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01572-0","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nobukazu Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd., and payments for lectures, including speakers\u2019 bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., Daiichi-Sankyo Co., Ltd., and Teijin Pharma Ltd. Sumito Ogawa has received payments for lectures from Tsumura Co., Ltd., and Daiichi-Sankyo Co., Ltd. Masayuki Iki, Yuki Fujita, Katsuyasu Kouda, Kenji Fujimori, Shinichi Nakatoh, Shigeyuki Ishii, and Junko Tamaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the MHLW (Ho0713-5-1498; 13 July 2023), the Ethics Committee of Osaka Medical and Pharmaceutical University (Approval number: 2023-028; 22 May 2023) and the Ethics Committee of Kansai Medical University (Approval number:2025315; 2 February 2026).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"We analyzed data provided by the MHLW which were completely anonymous. Therefore, informed consent from each patient was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Publication of the present manuscript was approved by the MHLW (No.2025\u2013243; 22 September 2025) and all authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"110"}}